De-Escalation of P2Y12 Receptor Inhibitor Therapy after Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention

about

De-Escalation of P2Y12 Receptor Inhibitor Therapy after Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention

Item

http://www.wikidata.org/entity/Q57143053

description

scientific article published on 01 October 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2018

@uk

name

De-Escalation of P2Y12 Recepto ...... utaneous Coronary Intervention

@en

De-Escalation of P2Y12 Recepto ...... utaneous Coronary Intervention

@nl

type

Item

label

De-Escalation of P2Y12 Recepto ...... utaneous Coronary Intervention

@en

De-Escalation of P2Y12 Recepto ...... utaneous Coronary Intervention

@nl

prefLabel

De-Escalation of P2Y12 Recepto ...... utaneous Coronary Intervention

@en

De-Escalation of P2Y12 Recepto ...... utaneous Coronary Intervention

@nl

P1476

De-Escalation of P2Y12 Recepto ...... utaneous Coronary Intervention

@en

P2093

Dirk Sibbing

http://www.w3.org/2001/XMLSchema#string

P2860

Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.

2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevati

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

Cytochrome p-450 polymorphisms and response to clopidogrel.

P304

863-872

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4070/KCJ.2018.0255

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Danny Kupka

P577

2018-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30238704

http://www.w3.org/2001/XMLSchema#string

P932

6158449

http://www.w3.org/2001/XMLSchema#string